Cybin (CYBN.NEO) approved for first-in-human dosing
Cybin (CYBN.NEO), a Canadian-based biopharmaceutical company working to transform psychedelics into therapeutics, announced today that it had received approval from an independent ethics committee in… Read More »Cybin (CYBN.NEO) approved for first-in-human dosing


